Veracyte Competitors

Veracyte (NASDAQ:VCYT) and Natera (NASDAQ:NTRA) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Valuation & Earnings

This table compares Veracyte and Natera's revenue, earnings per share and valuation.

Veracyte has higher earnings, but lower revenue than Natera. Veracyte is trading at a lower price-to-earnings ratio than Natera, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Veracyte and Natera, as provided by MarketBeat.

Veracyte presently has a consensus price target of $55.5714, suggesting a potential upside of 57.87%. Natera has a consensus price target of $114.70, suggesting a potential upside of 28.99%. Given Veracyte's higher possible upside, equities research analysts plainly believe Veracyte is more favorable than Natera.

Institutional & Insider Ownership

94.9% of Natera shares are held by institutional investors. 8.3% of Veracyte shares are held by insiders. Comparatively, 9.3% of Natera shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Veracyte has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Natera has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500.

Profitability

This table compares Veracyte and Natera's net margins, return on equity and return on assets.

Summary

Natera beats Veracyte on 8 of the 14 factors compared between the two stocks.

Invitae (NYSE:NVTA) and Veracyte (NASDAQ:VCYT) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.

Risk and Volatility

Invitae has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Invitae and Veracyte, as reported by MarketBeat.com.

Invitae presently has a consensus target price of $46.1667, suggesting a potential upside of 76.95%. Veracyte has a consensus target price of $55.5714, suggesting a potential upside of 57.87%. Given Invitae's higher probable upside, equities research analysts clearly believe Invitae is more favorable than Veracyte.

Valuation and Earnings

This table compares Invitae and Veracyte's gross revenue, earnings per share and valuation.

Veracyte has lower revenue, but higher earnings than Invitae. Veracyte is trading at a lower price-to-earnings ratio than Invitae, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

78.6% of Invitae shares are held by institutional investors. 2.9% of Invitae shares are held by insiders. Comparatively, 8.3% of Veracyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Invitae and Veracyte's net margins, return on equity and return on assets.

Summary

Veracyte beats Invitae on 8 of the 14 factors compared between the two stocks.

Veracyte (NASDAQ:VCYT) and CareDx (NASDAQ:CDNA) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Risk & Volatility

Veracyte has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, CareDx has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Veracyte and CareDx, as provided by MarketBeat.com.

Veracyte currently has a consensus target price of $55.5714, indicating a potential upside of 57.87%. CareDx has a consensus target price of $75.6667, indicating a potential upside of 17.84%. Given Veracyte's higher possible upside, research analysts clearly believe Veracyte is more favorable than CareDx.

Profitability

This table compares Veracyte and CareDx's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Veracyte and CareDx's top-line revenue, earnings per share (EPS) and valuation.

Veracyte has higher earnings, but lower revenue than CareDx. Veracyte is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Summary

CareDx beats Veracyte on 8 of the 13 factors compared between the two stocks.

Burning Rock Biotech (NASDAQ:BNR) and Veracyte (NASDAQ:VCYT) are both mid-cap business services companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Insider & Institutional Ownership

15.8% of Burning Rock Biotech shares are owned by institutional investors. 8.3% of Veracyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Burning Rock Biotech and Veracyte's revenue, earnings per share and valuation.

Burning Rock Biotech has higher earnings, but lower revenue than Veracyte.

Profitability

This table compares Burning Rock Biotech and Veracyte's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings for Burning Rock Biotech and Veracyte, as provided by MarketBeat.com.

Burning Rock Biotech currently has a consensus target price of $32.30, indicating a potential upside of 11.96%. Veracyte has a consensus target price of $55.5714, indicating a potential upside of 57.87%. Given Veracyte's higher possible upside, analysts clearly believe Veracyte is more favorable than Burning Rock Biotech.

Summary

Burning Rock Biotech beats Veracyte on 5 of the 9 factors compared between the two stocks.

Fulgent Genetics (NASDAQ:FLGT) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations for Fulgent Genetics and Veracyte, as provided by MarketBeat.com.

Fulgent Genetics currently has a consensus price target of $74.40, indicating a potential upside of 10.30%. Veracyte has a consensus price target of $55.5714, indicating a potential upside of 57.87%. Given Veracyte's stronger consensus rating and higher probable upside, analysts plainly believe Veracyte is more favorable than Fulgent Genetics.

Volatility & Risk

Fulgent Genetics has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.

Valuation & Earnings

This table compares Fulgent Genetics and Veracyte's gross revenue, earnings per share (EPS) and valuation.

Fulgent Genetics has higher earnings, but lower revenue than Veracyte. Veracyte is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Fulgent Genetics and Veracyte's net margins, return on equity and return on assets.

Institutional and Insider Ownership

33.4% of Fulgent Genetics shares are held by institutional investors. 45.0% of Fulgent Genetics shares are held by insiders. Comparatively, 8.3% of Veracyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Fulgent Genetics beats Veracyte on 10 of the 14 factors compared between the two stocks.

Veracyte (NASDAQ:VCYT) and Genetron (NASDAQ:GTH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Veracyte and Genetron, as provided by MarketBeat.com.

Veracyte currently has a consensus price target of $55.5714, suggesting a potential upside of 57.87%. Genetron has a consensus price target of $19.50, suggesting a potential upside of 8.94%. Given Veracyte's higher possible upside, analysts plainly believe Veracyte is more favorable than Genetron.

Insider & Institutional Ownership

19.6% of Genetron shares are owned by institutional investors. 8.3% of Veracyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Veracyte and Genetron's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Veracyte and Genetron's top-line revenue, earnings per share and valuation.

Veracyte has higher revenue and earnings than Genetron.

Summary

Genetron beats Veracyte on 6 of the 11 factors compared between the two stocks.